These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22343310)

  • 21. Cyclin-dependent kinase inhibitors sensitize tumor cells to nutlin-induced apoptosis: a potent drug combination.
    Cheok CF; Dey A; Lane DP
    Mol Cancer Res; 2007 Nov; 5(11):1133-45. PubMed ID: 18025259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.
    Park EJ; Choi KS; Yoo YH; Kwon TK
    Anticancer Drugs; 2013 Mar; 24(3):260-9. PubMed ID: 23187459
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
    Zheng T; Wang J; Chen X; Meng X; Song X; Lu Z; Jiang H; Liu L
    Tumour Biol; 2010 Aug; 31(4):287-95. PubMed ID: 20422343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73.
    Peirce SK; Findley HW
    Int J Oncol; 2009 May; 34(5):1395-402. PubMed ID: 19360352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.
    Huang B; Vassilev LT
    Aging (Albany NY); 2009 Sep; 1(10):845-54. PubMed ID: 20157557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
    Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
    Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
    Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
    Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers.
    Ohgami T; Kato K; Kobayashi H; Sonoda K; Inoue T; Yamaguchi S; Yoneda T; Wake N
    Cancer Sci; 2010 Jun; 101(6):1387-95. PubMed ID: 20331637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
    Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
    Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
    Guo Y; Li Y; Wang FF; Xiang B; Huang XO; Ma HB; Gong YP
    Int J Biochem Cell Biol; 2019 Jan; 106():8-20. PubMed ID: 30389549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MDM2 inhibitor nutlin-3a induces apoptosis and senescence in cutaneous T-cell lymphoma: role of p53.
    Manfé V; Biskup E; Johansen P; Kamstrup MR; Krejsgaard TF; Morling N; Wulf HC; Gniadecki R
    J Invest Dermatol; 2012 May; 132(5):1487-96. PubMed ID: 22377766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma.
    Van Maerken T; Speleman F; Vermeulen J; Lambertz I; De Clercq S; De Smet E; Yigit N; Coppens V; Philippé J; De Paepe A; Marine JC; Vandesompele J
    Cancer Res; 2006 Oct; 66(19):9646-55. PubMed ID: 17018622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2.
    Gu L; Zhu N; Findley HW; Zhou M
    Leukemia; 2008 Apr; 22(4):730-9. PubMed ID: 18273046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of MDM2 inhibitors on vascular endothelial growth factor-mediated tumor angiogenesis in human breast cancer.
    Xiong J; Yang Q; Li J; Zhou S
    Angiogenesis; 2014 Jan; 17(1):37-50. PubMed ID: 23907365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nutlin-3a is a potential therapeutic for ewing sarcoma.
    Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM
    Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
    Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MDM2 antagonist nutlin-3a sensitizes tumors to V-ATPase inhibition.
    Schneider LS; Ulrich M; Lehr T; Menche D; Müller R; von Schwarzenberg K
    Mol Oncol; 2016 Aug; 10(7):1054-62. PubMed ID: 27157929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
    Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB
    Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.